Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune Encephalomyelitis.
C57BL/6
EAE
EPM
MS
MS therapy
anxiety-like behavior
autoimmune disease
hippocampus
neuroinflammation
platelets
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
23
12
2018
revised:
21
01
2019
accepted:
27
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
6
2
2019
Statut:
epublish
Résumé
The neuropsychiatric symptoms of multiple sclerosis (MS), such as anxiety and depression, can result from disease activity itself as well as psychological reaction to an unfavorable diagnosis. Accordingly, the literature reports evidence of increased anxiety-like behavior in experimental autoimmune encephalomyelitis (EAE), an accepted MS model. Due to the recently described critical role of platelets in inflammation and autoimmune disease, we examined the relationship between platelets, inflammation, and anxiety-like behavior in EAE. In the elevated plus maze, EAE-induced C57BL/6J mice showed decreased time spent in the open arms relative to vehicle-only controls, demonstrating an increase in anxiety-like behavior. This effect occurred in the presence of platelet⁻neuron association, but absence of lymphocytic infiltration, in the hippocampal parenchyma. Platelet depletion at the pre-clinical disease stage, using antibody-mediated lysis prevented the EAE-induced increase in anxiety-like behavior, while no significant difference in distance moved was recorded. Furthermore, platelet depletion was also associated with reduction of the pro-inflammatory environment to control levels in the hippocampus and prevention of EAE disease symptomology. These studies demonstrate the high efficacy of a platelet-targeting approach in preventing anxiety-like symptoms and clinical manifestations of EAE and have implications for the treatment of neuropsychiatric symptoms in MS.
Identifiants
pubmed: 30717130
pii: jcm8020162
doi: 10.3390/jcm8020162
pmc: PMC6406682
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Neurol. 2001 Sep;50(3):389-400
pubmed: 11558796
Brain Behav Immun. 2002 Oct;16(5):533-43
pubmed: 12401467
Neurosci Biobehav Rev. 2005;29(8):1193-205
pubmed: 16084592
Brain. 2005 Nov;128(Pt 11):2705-12
pubmed: 16230320
J Neuropathol Exp Neurol. 2005 Dec;64(12):1101-7
pubmed: 16319720
Ann Neurol. 2006 Jul;60(1):12-21
pubmed: 16802293
Brain Pathol. 2007 Jan;17(1):38-44
pubmed: 17493036
J Neuropathol Exp Neurol. 2007 Sep;66(9):819-27
pubmed: 17805012
Arch Neurol. 2007 Oct;64(10):1416-22
pubmed: 17923625
Brain Pathol. 2009 Apr;19(2):238-53
pubmed: 18492094
J Neuroinflammation. 2008 Jun 27;5:27
pubmed: 18588683
Lancet Neurol. 2008 Sep;7(9):841-51
pubmed: 18703006
Prim Care Companion J Clin Psychiatry. 2008;10(4):318-24
pubmed: 18787677
J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):182-7
pubmed: 18829630
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Prog Neurobiol. 2010 Nov;92(3):386-404
pubmed: 20558237
J Neuroimmunol. 2011 Mar;232(1-2):51-62
pubmed: 21056916
J Vis Exp. 2011 Feb 02;(48):null
pubmed: 21339713
Circ Res. 2012 Apr 27;110(9):1202-10
pubmed: 22456181
Circ Res. 2012 Apr 27;110(9):1157-8
pubmed: 22539752
Exp Neurol. 2012 Oct;237(2):296-303
pubmed: 22836148
Exp Neurol. 2013 Mar;241:113-21
pubmed: 23291347
PLoS One. 2013;8(3):e58979
pubmed: 23555611
Int J Lab Hematol. 2013 Jun;35(3):254-61
pubmed: 23590652
Trends Cogn Sci. 2013 May;17(5):230-40
pubmed: 23597720
Thromb Haemost. 2013 Nov;110(5):888-93
pubmed: 23636306
Glia. 2014 Nov;62(11):1816-30
pubmed: 24470325
Nat Rev Neurol. 2014 Apr;10(4):225-38
pubmed: 24638138
J Neurosci Methods. 2014 Oct 30;236:44-50
pubmed: 25128721
BMC Neurosci. 2014 Sep 22;15:110
pubmed: 25242463
Oxid Med Cell Longev. 2015;2015:240918
pubmed: 26064417
Neuroscience. 2015 Sep 10;303:270-84
pubmed: 26141847
CNS Neurol Disord Drug Targets. 2015;14(7):915-35
pubmed: 26177741
Platelets. 2015;26(6):507-20
pubmed: 26196409
Mult Scler Relat Disord. 2014 Sep;3(5):555-64
pubmed: 26265267
Thromb Haemost. 2015 Aug 31;114(3):449-58
pubmed: 26293514
Circ Res. 2015 Oct 9;117(9):779-92
pubmed: 26294656
Crit Rev Clin Lab Sci. 2016 Dec;53(6):409-30
pubmed: 27282765
Mol Cell Biochem. 2016 Sep;420(1-2):85-94
pubmed: 27507559
Int J Mol Sci. 2016 Oct 14;17(10):
pubmed: 27754414
Acta Neurobiol Exp (Wars). 2016;76(4):269-281
pubmed: 28094818
Mol Cell Biochem. 2017 Jun;430(1-2):69-80
pubmed: 28210898
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):697-708
pubmed: 28285265
Neuroreport. 2018 Jan 3;29(1):19-24
pubmed: 29194293
Mol Neurobiol. 2018 Aug;55(8):6282-6306
pubmed: 29294244
Nat Rev Cardiol. 2018 Mar;15(3):181-191
pubmed: 29297508
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Lab Anim. 2018 Oct;52(5):470-478
pubmed: 29444620
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):567-576
pubmed: 29757405
PLoS One. 2018 Jul 6;13(7):e0200254
pubmed: 29979757
Lancet Neurol. 2018 Oct;17(10):918-926
pubmed: 30264730